RSS

Acute lymphoblastic leukaemia (ALL)

The US FDA has granted accelerated approval to Amgen’s Blincyto (blinatumomab) to treat adults and children with B-cell precursor acute lymphoblastic leukaemia who are in remission but still have minimal residual disease (MRD) more

News

Clinical-stage, biopharmaceutical start-up company, Autolus, steps into the chimeric antigen receptor (CAR)-T cell therapy fray with three new studies looking at the treatment of various cancers. more

News

Novartis has received approval for its chimeric antigen receptor T cell (CAR-T) therapy, Kymriah (tisagenlecleucel) suspension for intravenous infusion, formerly CTL019, from the US Food and Drug Administration (FDA). more

News